6533b858fe1ef96bd12b585e

RESEARCH PRODUCT

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion

T BöseltTimm GreulichPeter AlterManuel J. RichterMarco IdzkoAndreas HoffmannRoland BuhlKhodr TelloKhodr TelloAndreas Rembert KoczullaStefan KuhnertClaus VogelmeierBjörn BeutelAngelique Holland

subject

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyExacerbationAnti-IL-5-therapyCase Report03 medical and health sciences0302 clinical medicineEosinophiliamedicineEosinophiliaIntensive care medicineRespiratory systemInterleukin 5Asthmalcsh:RC705-779business.industryExacerbationlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmarespiratory tract diseasesClinical trial030228 respiratory system030220 oncology & carcinogenesisBreathingmedicine.symptombusinessMepolizumabmedicine.drug

description

We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack.The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma. Keywords: Anti-IL-5-therapy, Asthma, Eosinophilia, Exacerbation, Intensive care medicine

yearjournalcountryeditionlanguage
2019-08-01Respiratory Medicine Case Reports
https://doi.org/10.1016/j.rmcr.2019.100927